Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silmitasertib in Moderate COVID-19
NCT04663737Phase 2Completed
- Sponsor
- Senhwa Biosciences, Inc.
- Start
- Nov 2020
- Primary completion
- Aug 2021
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of silmitasertib in coronavirus disease 2019 (COVID-19), sponsored by Senhwa Biosciences, Inc.. Started Nov 2020; status: completed.
02
Drugs
silmitasertib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04663737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04663737.